WHO Press Conference
12 February 2016 10:00 - 10:30WHO is currently mapping existing R&D for Zika in order to prioritize medical products and approaches that should be fast-tracked into development.
Until today, most research that could be useful for Zika has been carried out on other flaviviruses – such as dengue or yellow fever.
WHO’s R&D efforts on Zika are part of the overall work on a roadmap – the R&D Blueprint - for better R&D preparedness based on the experience of the R&D work carried out during the Ebola outbreak. Dr Marie-Paule Kieny, Assistant Director-General, Health Systems and Innovation, WHO